View Older Stories View More Recent Stories

Apr 15, 2022 06:00AM China NMPA Approves Tislelizumab for Patients with Second-Line Esophageal Squamous Cell Carcinoma
Apr 11, 2022 06:00AM IRC Determines BRUKINSA® (Zanubrutinib) Demonstrates Superior Overall Response Rate Versus Ibrutinib in Final Response Analysis of ALPINE Trial in Chronic Lymphocytic Leukemia
Apr 8, 2022 07:00AM BeiGene to Present Clinical Results and Biomarker Data on Tislelizumab in Solid Tumors at the AACR Annual Meeting 2022
Apr 6, 2022 05:00AM BeiGene Announces European Medicines Agency Acceptance of Marketing Authorization Applications for Tislelizumab for the Treatment of Patients with ESCC and NSCLC
Mar 15, 2022 08:00AM BeiGene and Medison Announce Approval and National Reimbursement in Israel for BRUKINSA® (zanubrutinib) for the Treatment of Waldenström's Macroglobulinemia
Mar 11, 2022 07:00AM China NMPA Approves Tislelizumab for Patients with Microsatellite Instability-High or Mismatch Repair-Deficient Solid Tumors
Mar 3, 2022 07:00AM BeiGene Announces Health Canada Approval for BRUKINSA® (zanubrutinib) in Relapsed or Refractory Marginal Zone Lymphoma
Mar 1, 2022 05:30AM BeiGene to Present at the Cowen 42nd Annual Health Care Virtual Conference
Feb 25, 2022 07:00AM BeiGene Reports Fourth Quarter and Full Year 2021 Financial Results
Feb 22, 2022 07:03AM BeiGene (BGNE) Announces European Medicines Agency Acceptance of Applications for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia and Marginal Zone Lymphoma
Feb 22, 2022 07:00AM BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia
Feb 22, 2022 07:00AM BeiGene Announces European Medicines Agency Acceptance of Applications for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia and Marginal Zone Lymphoma
Feb 17, 2022 05:00AM BeiGene Announces Approval for BRUKINSA (zanubrutinib) by Swissmedic for Treatment of Adult Patients with Waldenström’s Macroglobulinemia
Feb 1, 2022 07:00AM Drs. Margaret Dugan and Alessandro Riva Appointed to BeiGene Board of Directors
Jan 28, 2022 05:00AM BeiGene Announces Acceptance of Supplemental New Drug Application in China for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia with Breakthrough Therapy Designation
Jan 24, 2022 05:00AM BeiGene Announces Positive Findings from Phase 3 Trial of Tislelizumab in Combination with Chemotherapy in First-Line Gastric or Gastroesophageal Junction Cancer
Jan 20, 2022 05:00AM BeiGene Announces Acceptance of a Supplemental New Drug Application in China for BRUKINSA (zanubrutinib) in Waldenström’s Macroglobulinemia
Dec 20, 2021 04:00AM BeiGene Announces Launch of Bioisland Innovation Center
Dec 15, 2021 04:00AM BeiGene Announces Authorisation of BRUKINSA (zanubrutinib) from the United Kingdom’s MHRA for the Treatment of Adults with Waldenström’s Macroglobulinemia in Great Britain
Dec 14, 2021 11:00PM BeiGene Announces Closing of Its RMB22.2 Billion (US$3.5 Billion) Initial Public Offering on the STAR Market of the Shanghai Stock Exchange in China
Dec 12, 2021 09:30AM BeiGene Presents Results from SEQUOIA Trial of BRUKINSA (zanubrutinib) in First-Line Chronic Lymphocytic Leukemia at the 63rd ASH Annual Meeting
Dec 11, 2021 09:30AM BeiGene Presents Updated Safety and Efficacy Findings on BRUKINSA (zanubrutinib) in BTK Inhibitor-Intolerant Patients with Relapsed or Refractory B-Cell Malignancies
Dec 10, 2021 06:15AM BeiGene (BGNE) Presents Results from Phase 3 Trial of Tislelizumab in Nasopharyngeal Cancer at ESMO
Dec 10, 2021 03:00AM BeiGene Presents Results from Phase 3 Trial of Tislelizumab in Nasopharyngeal Cancer at ESMO Immuno-Oncology Congress 2021
Dec 2, 2021 11:00PM BeiGene and EUSA Pharma Announce NMPA Approval of SYLVANT® (Siltuximab for Injection) in China for Idiopathic Multicentric Castleman Disease
Dec 2, 2021 11:00PM BeiGene and EUSA Pharma Announce NMPA Approval of SYLVANT® (Siltuximab for Injection) in China for Idiopathic Multicentric Castleman Disease
Dec 2, 2021 03:00AM BeiGene to Present New Clinical Data on Tislelizumab at ESMO IO Congress 2021
Nov 30, 2021 09:02AM BeiGene (BGNE) Announces Pricing of its RMB22.2 billion (US$3.5 billion) IPO on the STAR Market of the Shanghai Stock Exchange in China
Nov 30, 2021 09:00AM BeiGene Announces Pricing of its RMB22.2 billion (US$3.5 billion) Initial Public Offering on the STAR Market of the Shanghai Stock Exchange in China
Nov 23, 2021 05:01PM BeiGene (BGNE) Announces Approval of BRUKINSA in European Union for Treatment of Adults with Waldenstrom's Macroglobulinemia
Nov 23, 2021 05:00PM BeiGene Announces Approval of BRUKINSA (zanubrutinib) in the European Union for Treatment of Adults with Waldenström’s Macroglobulinemia
Nov 23, 2021 08:18AM BeiGene (BGNE) Launches Proposed Initial Public Offering on the STAR Market in China
Nov 23, 2021 08:15AM BeiGene Launches Proposed Initial Public Offering on the STAR Market in China
Nov 23, 2021 07:00AM BeiGene Closes on Property for New U.S. Manufacturing and Clinical R&D Center
Nov 22, 2021 07:00AM BeiGene Initiates First-in-Human Phase 1 Clinical Trial of Investigational TYK2 Inhibitor BGB-23339
Nov 14, 2021 07:00PM BeiGene and NewBridge Pharmaceuticals Announce Approval in Saudi Arabia of BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma
Nov 4, 2021 04:05PM BeiGene Reports Third Quarter 2021 Financial Results
Nov 4, 2021 09:00AM BeiGene to Present Clinical Data on BRUKINSA in Chronic Lymphocytic Leukemia at the 63rd ASH Annual Meeting
Oct 20, 2021 07:00AM BeiGene and Nanolek Announce Approval in Russia for BRUKINSA® (Zanubrutinib) for Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma
Oct 10, 2021 05:00PM BeiGene Announces BRUKINSA® (Zanubrutinib) Approved for Treatment of Patients with Mantle Cell Lymphoma
Oct 10, 2021 05:00PM BeiGene Announces BRUKINSA® (Zanubrutinib) Approved for Treatment of Patients with Mantle Cell Lymphoma in Australia
Oct 7, 2021 04:06PM BeiGene (BGNE) Announces First Regulatory Approval in Australia for BRUKINSA for Treatment of Patients with Waldenstrom's Macroglobulinemia
Oct 7, 2021 04:06PM BeiGene Announces First Regulatory Approval in Australia for BRUKINSA® (Zanubrutinib) for Treatment of Patients with Waldenström’s Macroglobulinemia
Oct 7, 2021 04:05PM BeiGene Announces First Regulatory Approval in Australia for BRUKINSA® (Zanubrutinib) for Treatment of Patients with Waldenström’s Macroglobulinemia
Sep 20, 2021 07:00AM BeiGene Announces Inclusion in FTSE Russell Indices
Sep 17, 2021 08:01AM BeiGene (BGNE) Announces Positive CHMP Opinion for BRUKINSA® (Zanubrutinib) for the Treatment of Adults with Waldenström’s Macroglobulinemia
Sep 17, 2021 08:00AM BeiGene Receives Positive CHMP Opinion for BRUKINSA® (Zanubrutinib) for the Treatment of Adults with Waldenström’s Macroglobulinemia
Sep 15, 2021 07:03AM BeiGene (BGNE) BRUKINSA® Granted Accelerated Approval in Relapsed or Refractory Marginal Zone Lymphoma
Sep 15, 2021 07:00AM U.S. FDA Grants BRUKINSA® (Zanubrutinib) Accelerated Approval in Relapsed or Refractory Marginal Zone Lymphoma
Sep 13, 2021 06:18AM BeiGene (BGNE) Announces U.S. FDA Acceptance of BLA for Tislelizumab in Esophageal Squamous Cell Carcinoma
View More Recent Stories View Older Stories